Am J Otolaryngol Head Neck Surg | Volume 1, Issue 6 | Case Report | Open Access

Lenvatinib for Radioactive Iodine-Refractory Papillary Thyroid Carcinoma: A Case Report

Jose Reyes and Pedro R Leon*

Department of Clinical Oncology and Radiation Oncology, Centro Medico National del Norwest IMSS, Mexico

*Correspondance to: Pedro R Leon 

Fulltext PDF

Abstract

Thyroid cancer is the main example of neoplasia that affects endocrine glands, by frequency of presentation (9th place in world incidence 2018). Around 90% of thyroid carcinomas will correspond to the Differentiated group, obtaining adequate survival >80% at 40 years. 15% to 20% of the patients will not respond or will lose the ability to respond to radioactive Iodine, reducing the survival in 3 years to 5 years. We present the case of a female patient with criteria of Radioactive Iodine-Refractory and at the beginning had voluminous metastatic disease. The patient was assessed in a multidisciplinary manner, and started with tyrosine kinase inhibitor, obtaining a close to complete response after one year of treatment. Because hypertension, diarrhea, fatigue, and hepatic dysfunction are very common, close attention should be paid, we decided to prepare this report where lenvatinib was proved to be remarkably effective after several other ineffective multidisciplinary management.

Keywords:

Papillary thyroid cancer; Radioactive iodine-refractory; Lenvatinib

Citation:

Reyes J, Leon PR. Lenvatinib for Radioactive Iodine-Refractory Papillary Thyroid Carcinoma: A Case Report. Am J Otolaryngol Head Neck Surg. 2018;1(6):1029.

Subscribe to Our Newsletter